JP2019507721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507721A5 JP2019507721A5 JP2018528588A JP2018528588A JP2019507721A5 JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5 JP 2018528588 A JP2018528588 A JP 2018528588A JP 2018528588 A JP2018528588 A JP 2018528588A JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5
- Authority
- JP
- Japan
- Prior art keywords
- idh1
- mutation
- composition
- ras
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDYPYTQPBOKFBU-QQXFXQEMSA-N CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N Chemical compound CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N SDYPYTQPBOKFBU-QQXFXQEMSA-N 0.000 description 1
- ZRRBGUOZDZSRFF-NBTWKBOSSA-N N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O Chemical compound N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O ZRRBGUOZDZSRFF-NBTWKBOSSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021089138A JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263580P | 2015-12-04 | 2015-12-04 | |
| US62/263,580 | 2015-12-04 | ||
| US201662300721P | 2016-02-26 | 2016-02-26 | |
| US62/300,721 | 2016-02-26 | ||
| PCT/US2016/064832 WO2017096309A1 (en) | 2015-12-04 | 2016-12-02 | Methods of treatment of malignacies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089138A Division JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507721A JP2019507721A (ja) | 2019-03-22 |
| JP2019507721A5 true JP2019507721A5 (https=) | 2020-01-16 |
| JP6892448B2 JP6892448B2 (ja) | 2021-06-23 |
Family
ID=57610403
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528588A Expired - Fee Related JP6892448B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性腫瘍の処置の方法 |
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200268726A1 (https=) |
| EP (2) | EP3383433A1 (https=) |
| JP (4) | JP6892448B2 (https=) |
| KR (2) | KR102924995B1 (https=) |
| CN (1) | CN108883184A (https=) |
| AU (2) | AU2016362425B2 (https=) |
| CA (2) | CA3007363A1 (https=) |
| ES (1) | ES2905915T3 (https=) |
| IL (4) | IL298663A (https=) |
| MA (1) | MA43374A (https=) |
| MX (2) | MX391229B (https=) |
| WO (2) | WO2017096150A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| EP3561077B1 (en) * | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| SG11201803088PA (en) | 2015-10-15 | 2018-05-30 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| US11311527B2 (en) * | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| CA3133376A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| WO2021168283A1 (en) * | 2020-02-19 | 2021-08-26 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| CA3186380A1 (en) * | 2020-07-24 | 2022-01-27 | Molly ADAM | Spray drying of supersaturated solutions of api with acetic acid |
| WO2024229332A1 (en) * | 2023-05-03 | 2024-11-07 | Memorial Sloan-Kettering Cancer Center | Anti-cancer treatments and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| NZ627096A (en) * | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| JP2015512630A (ja) * | 2012-03-12 | 2015-04-30 | メモリアル スローン−ケタリング キャンサー センター | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| CA2842635A1 (en) | 2014-01-20 | 2015-07-20 | University Health Network | Pre-cancerous cells and their identification in the prevention and treatment of cancer |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| BR122023021436A2 (pt) | 2014-03-14 | 2023-12-12 | Les Laboratoires Servier | Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos |
| KR20240010105A (ko) * | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
-
2016
- 2016-12-02 IL IL298663A patent/IL298663A/en unknown
- 2016-12-02 ES ES16816809T patent/ES2905915T3/es active Active
- 2016-12-02 KR KR1020187019185A patent/KR102924995B1/ko active Active
- 2016-12-02 MX MX2018006745A patent/MX391229B/es unknown
- 2016-12-02 WO PCT/US2016/064600 patent/WO2017096150A1/en not_active Ceased
- 2016-12-02 EP EP16816817.7A patent/EP3383433A1/en not_active Withdrawn
- 2016-12-02 MX MX2018006831A patent/MX380596B/es unknown
- 2016-12-02 KR KR1020187018928A patent/KR20180086255A/ko not_active Ceased
- 2016-12-02 US US15/781,019 patent/US20200268726A1/en not_active Abandoned
- 2016-12-02 JP JP2018528588A patent/JP6892448B2/ja not_active Expired - Fee Related
- 2016-12-02 IL IL299563A patent/IL299563A/en unknown
- 2016-12-02 US US15/368,439 patent/US10188656B2/en active Active
- 2016-12-02 AU AU2016362425A patent/AU2016362425B2/en active Active
- 2016-12-02 CN CN201680080463.0A patent/CN108883184A/zh active Pending
- 2016-12-02 AU AU2016363011A patent/AU2016363011B2/en not_active Ceased
- 2016-12-02 JP JP2018528735A patent/JP6852073B2/ja active Active
- 2016-12-02 CA CA3007363A patent/CA3007363A1/en active Pending
- 2016-12-02 WO PCT/US2016/064832 patent/WO2017096309A1/en not_active Ceased
- 2016-12-02 MA MA043374A patent/MA43374A/fr unknown
- 2016-12-02 CA CA3007218A patent/CA3007218A1/en not_active Abandoned
- 2016-12-02 EP EP16816809.4A patent/EP3383400B1/en active Active
-
2018
- 2018-06-03 IL IL259787A patent/IL259787A/en unknown
- 2018-06-03 IL IL259783A patent/IL259783A/en unknown
-
2021
- 2021-03-10 JP JP2021038684A patent/JP2021098740A/ja active Pending
- 2021-05-12 US US17/318,606 patent/US20220000878A1/en not_active Abandoned
- 2021-05-27 JP JP2021089138A patent/JP2021121636A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507721A5 (https=) | ||
| JP2019502669A5 (https=) | ||
| JP2021098740A5 (https=) | ||
| JP2018535951A5 (https=) | ||
| JP2018536636A5 (https=) | ||
| JP2019533670A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP2019513694A5 (https=) | ||
| Wilson et al. | Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma | |
| Sundar et al. | Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers | |
| JP2020514311A5 (https=) | ||
| JP2014523516A5 (https=) | ||
| JP2018534286A5 (https=) | ||
| Wang et al. | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers | |
| Oza et al. | Homologous recombination repair deficiency as a therapeutic target in sarcoma | |
| JP2018526376A5 (https=) | ||
| JP2017508805A5 (https=) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| JP2018534288A5 (https=) | ||
| Wells Jr et al. | Update: the status of clinical trials with kinase inhibitors in thyroid cancer | |
| Ettrich et al. | Regorafenib | |
| Long et al. | Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment | |
| JP2019506392A5 (https=) | ||
| WO2020046767A1 (en) | Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors | |
| JP2019511550A5 (https=) |